Omeros Co. (OMER) Lifted to Hold at Zacks Investment Research
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Several other research analysts also recently commented on OMER. Maxim Group set a $19.00 price target on shares of Omeros and gave the company a buy rating in a report on Saturday, March 11th. WBB Securities reissued a buy rating and issued a $75.00 price target on shares of Omeros in a report on Thursday, November 17th. Wedbush reissued an outperform rating and issued a $47.00 price target on shares of Omeros in a report on Tuesday, February 21st. Finally, FBR & Co reissued a buy rating on shares of Omeros in a report on Thursday, March 2nd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Omeros currently has an average rating of Buy and an average target price of $33.38.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/omeros-co-omer-lifted-to-hold-at-zacks-investment-research.html
Shares of Omeros (NASDAQ:OMER) opened at 11.75 on Wednesday. The firm’s market capitalization is $504.25 million. The company has a 50-day moving average price of $11.05 and a 200-day moving average price of $10.51. Omeros has a 12-month low of $7.20 and a 12-month high of $16.38.
Your IP Address:
Institutional investors have recently modified their holdings of the company. Gradient Investments LLC boosted its position in shares of Omeros by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 814 shares during the last quarter. Eidelman Virant Capital acquired a new position in shares of Omeros during the third quarter worth approximately $1,763,000. Bank of Montreal Can boosted its position in shares of Omeros by 20.2% in the third quarter. Bank of Montreal Can now owns 2,015,248 shares of the biopharmaceutical company’s stock worth $22,490,000 after buying an additional 338,263 shares during the last quarter. Nwam LLC boosted its position in shares of Omeros by 12.5% in the third quarter. Nwam LLC now owns 23,393 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 2,600 shares during the last quarter. Finally, Chicago Equity Partners LLC boosted its position in shares of Omeros by 67.6% in the third quarter. Chicago Equity Partners LLC now owns 153,080 shares of the biopharmaceutical company’s stock worth $1,708,000 after buying an additional 61,755 shares during the last quarter. Institutional investors own 47.94% of the company’s stock.
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.